1063 related articles for article (PubMed ID: 19000581)
21. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
Colás C; Monzón S; Venturini M; Lezaun A
J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
23. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
24. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
25. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
Cudowska B; Kaczmarski M; Restani P
Rocz Akad Med Bialymst; 2005; 50():268-73. PubMed ID: 16358981
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
27. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
[TBL] [Abstract][Full Text] [Related]
28. Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens.
Aghayan-Ugurluoglu R; Ball T; Vrtala S; Schweiger C; Kraft D; Valenta R
J Allergy Clin Immunol; 2000 Apr; 105(4):803-13. PubMed ID: 10756233
[TBL] [Abstract][Full Text] [Related]
29. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
30. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
31. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
[TBL] [Abstract][Full Text] [Related]
32. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
33. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.
Nony E; Bouley J; Le Mignon M; Lemoine P; Jain K; Horiot S; Mascarell L; Pallardy M; Vincentelli R; Leone P; Roussel A; Batard T; Abiteboul K; Robin B; de Beaumont O; Arvidsson M; Rak S; Moingeon P
Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber.
Meyer W; Narkus A; Salapatek AM; Häfner D
Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350
[TBL] [Abstract][Full Text] [Related]
35. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
36. Molecular composition and biological activity of commercial birch pollen allergen extracts.
Focke M; Marth K; Valenta R
Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
[TBL] [Abstract][Full Text] [Related]
37. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
Movérare R; Elfman L; Vesterinen E; Metso T; Haahtela T
Allergy; 2002 May; 57(5):423-30. PubMed ID: 11972482
[TBL] [Abstract][Full Text] [Related]
38. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
39. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
[TBL] [Abstract][Full Text] [Related]
40. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
